Shangya Technology Valuation

Is 6130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6130 (NT$25.1) is trading above our estimate of fair value (NT$10.67)

Significantly Below Fair Value: 6130 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6130?

Key metric: As 6130 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6130. This is calculated by dividing 6130's market cap by their current revenue.
What is 6130's PS Ratio?
PS Ratio	5.4x
Sales	NT$206.46m
Market Cap	NT$1.11b

6130 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.3x
Enterprise Value/EBITDA	1282.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6130's PS Ratio compare to its peers?

The above table shows the PS ratio for 6130 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
3118 Level Biotechnology	1.5x	n/a	NT$1.0b
4173 Arich Enterprise	1.3x	n/a	NT$1.5b
4745 Cowealth Medical Holding	0.4x	n/a	NT$1.6b
6496 Excelsior Biopharma	1.7x	n/a	NT$1.4b
6130 Shangya Technology	5.4x	n/a	NT$1.1b

Price-To-Sales vs Peers: 6130 is expensive based on its Price-To-Sales Ratio (5.4x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does 6130's PS Ratio compare vs other companies in the TW Healthcare Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
4745 Cowealth Medical Holding	0.4x	n/a	US$48.87m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6130 is expensive based on its Price-To-Sales Ratio (5.4x) compared to the TW Healthcare industry average (1.7x).

Price to Sales Ratio vs Fair Ratio

What is 6130's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6130 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6130's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Concord Medical

NT$866.7m

Provides hospital management support services primarily in Taiwan.

6518

NT$26.20

1.4%

4.4%

Universal Vision Biotechnology

NT$17.5b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

-25.9%

Crystalvue Medical

NT$2.2b

Designs, manufactures, and sells ophthalmic medical equipment worldwide.

6527

NT$87.90

-2.7%

1.0%